Skip to main content
SupplementScience

AREDS2 Formula Research & Evidence

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Strong

The AREDS2 trial (2013, JAMA) is the definitive study on nutritional supplementation for AMD. Sponsored by the NIH National Eye Institute, it enrolled 4,203 participants aged 50-85 with intermediate AMD or advanced AMD in one eye. The study confirmed that lutein/zeaxanthin was a safe and effective substitute for beta-carotene, eliminating the lung cancer risk in smokers. A 10-year follow-up (Chew et al., 2022) confirmed that the lutein/zeaxanthin formulation outperformed beta-carotene for AMD prevention.

Evidence by Condition

ConditionStudied DoseEvidence
Intermediate AMD (both eyes)Full AREDS2 formula dailyStrong
Advanced AMD in one eyeFull AREDS2 formula dailyStrong
Early AMD / preventionNot proven beneficial — AREDS2 studied intermediate-to-advanced AMDModerate
Full AREDS2 Formula Guide

References

  1. (). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. DOI
  2. (). Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmology. DOI
  3. (). A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Archives of Ophthalmology. DOI